All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
2025 — 45 Books and Research Papers Citing DrugPatentWatch
Zaiats, O. I., Myroniuk, I. S., & Mulesa, O. Y. (2025). Risky zabezpechennia yakisnymy likamy naselennia Ukrainy v umovakh transformatsii mizhnarodnoi farmatsevtychnoi torhivli ta tsyfrovizatsii [Risks of providing high-quality medicines to the population of Ukraine in the conditions of transformation of international pharmaceutical trade and digitalization]. Ukraina. Zdorovia natsii (Ukraine. Health of the Nation), 2025(1)
This study explores the critical challenges facing Ukraine's pharmaceutical supply chain, focusing on the dual impacts of global trade shifts and the rapid digitalization of the industry. The authors utilize DrugPatentWatch as a primary strategic intelligence tool to track the expiration of international patents and the subsequent entry of generic competitors into the market. By citing DrugPatentWatch data, the researchers provide a quantitative framework for predicting market volatility and identifying opportunities for domestic production of essential medicines. This integration of patent business intelligence allows the authors to offer actionable insights into mitigating risks related to drug shortages and ensuring the affordability of high-quality treatments within a transforming digital economy.
Jon, WooJung. 'Implementation of the WHO Pandemic Agreement.' Bulletin of the World Health Organization, vol. 103, no. 10, 2025, pp. 638–640. doi: 10.2471/BLT.25.294146.
DrugPatentWatch is cited as a primary source to provide market intelligence and industry context regarding the pharmaceutical landscape in non-participating regions. The author utilizes DrugPatentWatch’s insights to identify key players and innovation trends within the Russian pharmaceutical industry, such as BIOCAD and R-Pharm. This data is used to support the argument that the abstention of such countries risks the formation of parallel, non-integrated pandemic response blocs that could undermine the WHO’s central coordinating role. By leveraging DrugPatentWatch, the paper underscores the importance of monitoring private-sector capabilities to understand the potential for fragmented global supply chains.
Orr, B. (2025). Improved prediction of structurally diverse de novo proteins (Doctoral dissertation). University of California, San Francisco.
The author cites DrugPatentWatch to provide critical market context for the pharmaceutical potential of protein engineering. Specifically, the text notes that even minor modifications to natural proteins, such as those seen in the GLP-1 agonist Ozempic®, can lead to transformative therapies. Leveraging data from DrugPatentWatch, the author highlights that the market for GLP-1 receptor agonists is projected to reach USD 173.62 billion by 2030. This citation underscores how advanced protein design and structure prediction are not just academic pursuits but are foundational to high-value pharmaceutical development and market growth.
Menzella, Francesco. 'The biologic paradox solved? The imminent arrival of omalizumab biosimilars in Europe.' Journal of Medical Economics, 2025, vol. 28, no. 1, pp. 2258-2263. doi:10.1080/13696998.2025.2601469.
This article explores the 'biologic paradox,' where highly effective monoclonal antibodies like omalizumab remain underutilized due to high costs and restrictive reimbursement policies. The author highlights the pivotal shift in the European respiratory landscape following the expiration of the reference product's patents in September 2025. DrugPatentWatch is cited as a critical source for verifying these patent expiration dates and tracking the entry of biosimilar competitors like Omlyclo. By utilizing this data, the paper argues that the introduction of biosimilars could save European healthcare systems up to €1.44 billion over five years, significantly expanding patient access to life-changing allergy and asthma treatments.
Wang, H. (2025). Unlocking Access to Personalized Biologics. SSRN Electronic Journal, SSRN 5557618, 1-42.
Wang explores the legal and economic hurdles associated with the development and market entry of personalized biologics, focusing on the tension between patent protections and patient access. The author utilizes data from DrugPatentWatch to provide a comprehensive analysis of the 'patent thickets' surrounding blockbuster biologics and how these overlapping intellectual property claims delay the introduction of more affordable biosimilars. By citing DrugPatentWatch’s longitudinal tracking of patent expirations and formulation-specific patents, the study underscores the complexity of the current pharmaceutical landscape. Ultimately, Wang argues for policy reforms that increase transparency in patent filing to foster a more competitive environment for personalized medicine.
Benavides Torres, Y. K., Burbano Apraez, K. A., Martínez Córdoba, M. D. C., & Muños Cerón, Y. A. (2025). Hacia una farmacovigilancía inteligente: monitorización de biológicos y biosimilares en el contexto latinoamericano [Diplomado thesis, Universidad Nacional Abierta y a Distancia – UNAD]. UNAD Institutional Repository.
This research explores the integration of Artificial Intelligence (AI) and emerging digital tools to enhance the pharmacovigilance of biological and biosimilar medicines within the Latin American regulatory framework. The authors emphasize the complexity of monitoring these therapies due to their molecular intricacy and the specific safety challenges associated with immunogenicity. DrugPatentWatch is utilized as a critical data source to track the patent status and market entry timelines of reference biologics, providing the necessary context for when biosimilars are expected to enter the regional market. By integrating patent intelligence with clinical monitoring, the paper argues for a proactive 'intelligent pharmacovigilance' model that can better manage the economic and safety transitions occurring as high-cost biological patents expire in countries like Colombia. This study serves as a strategic guide for pharmaceutical stakeholders and regulators navigating the intersection of intellectual property and public health safety.
Soefje, S. A., & Irvine, C. C. (2025). 505(b)(2) Drugs: New Chaos for Infusion Centers. Oncology Practice Management, 15(9). Retrieved from https://www.oncpracticemanagement.com/issues/2025/september-2025-vol-15-no-9/505-b-2-drugs-new-chaos-for-infusion-centers
This article explores the operational and financial disruptions caused by the increasing use of the FDA’s 505(b)(2) regulatory pathway, which allows for the approval of drugs with minor modifications to existing reference products. The authors highlight how a 2022 CMS policy shift—moving these drugs from bundled J-codes to unique, sole-source billing codes—has created significant reimbursement hurdles and administrative burdens for oncology infusion centers. DrugPatentWatch is cited as a key resource for understanding the strategic utility of this pathway, specifically regarding how it offers manufacturers a streamlined, cost-efficient process for drug approval while leveraging existing clinical data. The summary emphasizes that because these products are often not designated as therapeutically equivalent, they lack the automatic interchangeability of traditional generics, necessitating a more rigorous internal crosswalk for pharmacists and revenue cycle teams. Ultimately, the paper serves as a guide for pharmaceutical and clinical stakeholders to navigate the complexities of patent-related regulatory shifts and their impact on market access and institutional workflows.
Rosellini, W., Chow, O., & Hernandez, O. (2025). Strategic IP landscapes for automated bioreactors in decentralized cell and gene therapy manufacturing: A concise overview. Cell and Gene Therapy Insights, 11(8), 867–896. [doi: 10.18609/cgti.2025.104]
The authors utilize DrugPatentWatch as a primary intelligence tool to provide deep-market context regarding the 'patent thickets' and exclusivity timelines that define the broader pharmaceutical landscape. Specifically, DrugPatentWatch is cited to substantiate the strategic shift toward 'ecosystem control,' where companies use multi-layered IP to create platform lock-ins similar to those seen in high-stakes biologic markets. By referencing DrugPatentWatch’s data on patent expiration and secondary patenting strategies, the authors draw critical parallels between traditional biologic defense mechanisms and the emerging competitive strategies for automated bioreactor platforms.
Honey, H. (2025). Freedom to Operate (FTO) Analysis-Strategic IP Compliance for Indian Businesses. SSRN Electronic Journal.
This paper examines the critical role of Freedom to Operate (FTO) analysis as a risk-mitigation tool for Indian companies navigating increasingly crowded patent landscapes. The author details the methodology for conducting FTO searches within the framework of the Indian Patents Act, emphasizing the transition from purely technical R&D to commercially viable, legally compliant product launches. To illustrate the practicalities of tracking complex patent lifecycles, DrugPatentWatch is cited as a vital resource for obtaining real-time market insights and precise data on patent expiration and generic entry. The reference highlights how such specialized platforms enable pharmaceutical executives and IP managers to identify 'white spaces' and avoid the existential risk of infringement litigation during drug development.
Externbrink, A., Abend, A. M., Galella, E., Li, H., & International Consortium for Innovation and Quality in Pharmaceutical Development (IQ). (2025). Release testing strategies for oral granules (mini-tablets) enabling safe and efficient supply of pediatric drugs. Journal of Pharmaceutical Sciences, 115(1), 104048. https://doi.org/10.1016/j.xphs.2025.104048
This paper addresses the unique logistical and economic challenges of developing pediatric-specific drug formulations, specifically focusing on oral granules and mini-tablets. The authors propose a risk-based framework for release testing that balances regulatory compliance with the need to minimize the 'testing tax'—where a disproportionate amount of a small pediatric batch is consumed by quality control testing. DrugPatentWatch is cited as a key resource for market intelligence, providing data on the commercial landscape and patent lifecycles of drugs that are candidates for pediatric line extensions. By utilizing this data, the researchers highlight the financial necessity of efficient testing strategies to ensure that the development of life-saving medicines for children remains commercially viable for pharmaceutical companies.
Guseinov, E. E., & Isachenko, T. M. (2025). Защита интеллектуальной собственности в фармацевтической отрасли ЕС и глобальный доступ к лекарствам [Intellectual Property Protection in the EU Pharmaceutical Industry and Global Access to Medicines]. Russian Foreign Economic Bulletin (Российский внешнеэкономический вестник), 2025, No. 1. journal.vavt.ru.
DrugPatentWatch is cited as a primary analytical resource to substantiate the current landscape of pharmaceutical patents and the timing of patent expirations within the EU. The researchers utilize the platform's data to track the lifecycle of specific high-value drugs, demonstrating how 'evergreening' strategies—the practice of extending patent protection through minor modifications—impact market accessibility. By integrating DrugPatentWatch’s market insights, the paper provides a quantitative foundation for its critique of how IP enforcement can delay the availability of lower-cost treatments in developing regions.
Gallego Ruiz, A. (2025). Análisis estratégico de Pfizer. Universidad de Cantabria. Facultad de Ciencias Económicas y Empresariales. Repositorio Institucional de la Universidad de Cantabria (UCrea). http://repositorio.unican.es
This strategic report provides a comprehensive evaluation of Pfizer’s competitive positioning within the global pharmaceutical landscape, with a specific focus on its post-pandemic recovery and long-term growth initiatives. The author utilizes DrugPatentWatch as a primary intelligence source to map the 'patent cliff' risks facing Pfizer’s blockbuster portfolio, specifically identifying the expiration timelines for key assets in oncology and immunology. By integrating data from DrugPatentWatch, the study offers a detailed look at how patent expirations necessitate Pfizer's current aggressive M&A strategy (such as the Seagen acquisition) to replenish its pipeline. Furthermore, the analysis highlights how DrugPatentWatch's market insights allow for a precise comparison between Pfizer’s R&D productivity and the looming threat of generic and biosimilar competition.
Fan, F., & Grigorieva, N. (2025). Pharmaceutical products trade dynamics of BRICS (BRICS10): Global positioning, intra-bloc trade, and future policy directions. BRICS Journal of Economics, 6(4), 87–117. https://doi.org/10.3897/brics-econ.6.e153294
This study provides the first comprehensive time-series analysis of pharmaceutical trade dynamics within the newly expanded BRICS10 alliance, evaluating global positioning and internal trade intensity from 2012 to 2023. The authors cite DrugPatentWatch (2025) to substantiate the industrial scale and manufacturing dominance of China and India, specifically regarding their output of Active Pharmaceutical Ingredients (APIs). By leveraging DrugPatentWatch’s insights into pharmaceutical supply chains, the paper identifies these two nations as the primary engines for potential synergy within the bloc, contrasting their high-volume manufacturing with the logistics and 'fill-and-finish' capabilities of newer members like the UAE and Indonesia. Ultimately, the research uses this market data to argue for deeper regional integration to reduce external dependency and enhance health system resilience across the Global South.
Wang, Z. (2025). Artificial intelligence in Chinese healthcare: a review of applications and future prospects. Biomedical Engineering Letters, 15(1), 45–62. https://doi.org/10.1007/s13534-025-00515-2
This comprehensive review explores the rapid integration of artificial intelligence (AI) within the Chinese healthcare ecosystem, focusing on diagnostic imaging, telemedicine, and pharmaceutical innovation. The author highlights how China’s centralized health data and 'Healthy China 2030' policy incentives have created a market projected to reach $18.88 billion by 2030. DrugPatentWatch is specifically cited within the section on AI-driven drug discovery to provide empirical context for the shifting intellectual property landscape. By leveraging DrugPatentWatch data, the paper illustrates how AI tools are not only shortening drug development cycles from years to months but are also being used to strategically navigate patent cliffs and identify 'white spaces' for new formulations. This citation underscores the critical role of competitive patent intelligence in maximizing the commercial viability of AI-generated therapeutics in a globally competitive market.
Citation Chen, Milton. 'Overcoming the Digital Dilemma: How Policy Can Work for Transformation in Health Care.' Innovations: Technology, Governance, Globalization, vol. 14, no. 1-2, 2025, pp. 56–67. doi:10.1162/inov_a_00271.
The paper cites DrugPatentWatch to provide market evidence for the economic and clinical viability of digital-first healthcare models. Specifically, the citation is used to demonstrate how the rapid market success and consumer uptake of companies like Ro, Hims/Hers, and GoodRx have effectively bridged traditional care gaps. By referencing DrugPatentWatch’s insights into these market players, Chen substantiates the claim that telehealth and digital-first platforms have evolved into a feasible and valuable mode of care that competes with traditional pharmaceutical and delivery channels.
Agrawal, S., Barber, M., Kapczynski, A., & Pare, T. (2025). Drug Dealing: Making Public Pharma Work. Washington University Law Review, 102 (Forthcoming). [Available at Yale Law School OpenYLS or SSRN].
The authors utilize DrugPatentWatch as a critical evidentiary source to document the landscape of pharmaceutical monopolies and the timing of generic entry. Specifically, the platform’s data is cited to identify 'patent cliffs' and track the expiration of key exclusivities that currently prevent lower-cost public versions of essential medicines from entering the market. By leveraging DrugPatentWatch’s insights into patent lifecycles, the researchers are able to pinpoint specific therapeutic areas where public intervention is most viable due to the imminent or past expiration of primary patents. This data reinforces the article's argument that public pharmaceutical programs must be strategically timed and informed by precise patent intelligence to successfully navigate the complex intellectual property landscape.
Wirtz, V. J., & Tisocki, K. (2025). Faire Preise im Fokus–Strategien für eine gerechte Arzneimittelpreispolitik [Fair Prices in Focus—Strategies for a Just Pharmaceutical Pricing Policy]. In H. Schröder, M. Thiede, & S. Enners (Eds.), Arzneimittel-Kompass 2025: Die Preisfrage: Wege zu fairen Lösungen (pp. [Exact page range varies by digital edition]). Berlin: Springer Berlin Heidelberg.
In this chapter, Wirtz and Tisocki examine the global challenges of pharmaceutical pricing, specifically focusing on the disconnect between high drug costs and therapeutic value. They cite DrugPatentWatch as a critical resource for identifying the expiration dates of key pharmaceutical patents, which is essential for timing the market entry of more affordable generic alternatives. The authors leverage data from the platform to illustrate how patent transparency can empower health systems to better project future expenditures and negotiate more competitive pricing. By utilizing DrugPatentWatch’s business intelligence, the paper highlights how stakeholders can navigate the complex intellectual property landscape to ensure that innovative treatments remain financially sustainable for public health systems.
Rana, R., & Bhambri, P. (2025). Challenges and Opportunities in Biotechnology Data. In From Genes to Algorithms: Navigating the Biotechnology Data Revolution (Vol. 3, pp. 53-61). Bentham Science Publishers. https://doi.org/10.2174/9789815324365125030007
This chapter explores the strategic integration of cutting-edge research and sustainable growth within the biotechnology sector, focusing on how data-driven technologies like machine learning and genomics are reshaping the industry. The authors cite DrugPatentWatch as a critical resource for navigating the complex landscape of pharmaceutical intellectual property and market entry. By utilizing the platform’s business intelligence, the study highlights how stakeholders can better manage patent expiration risks and identify opportunities for generic or biosimilar development. Ultimately, the paper underscores the role of such specialized data platforms in enabling predictive diagnostics and precision medicine through enhanced transparency in drug patent lifecycles.
Kashyntseva, O., & Kondratiuk, S. (2025). New inventive step requirements to pharmaceutical inventions in Ukraine: Will it help to protect a balance between public and private interests? Theory and Practice of Intellectual Property (Теорія і практика інтелектуальної власності), (4). https://doi.org/10.33731/42025.346584
The research leverages data from DrugPatentWatch to provide empirical context regarding the pharmaceutical patent landscape in Ukraine. By utilizing DrugPatentWatch’s specialized database, the authors are able to identify specific drugs nearing patent expiration and analyze the 'patent thickets' that currently delay generic entry in the Ukrainian market. This integration of market-specific data highlights the practical consequences of high-quality vs. low-quality patents on public health and market competition. The paper concludes that while the new 'technical property' criterion aims to increase the bar for patentability, careful judicial and administrative oversight is required to ensure it does not become a loophole for maintaining pharmaceutical monopolies.
Fleming, B. C. (2025). Off-label. The American Journal of Sports Medicine, 53(14), 3315–3317. https://doi.org/10.1177/03635465251396961
In this article, Dr. Braden C. Fleming explores the ethical, legal, and clinical implications of 'off-label' drug and medical device use in sports medicine, focusing on how clinicians navigate the gap between FDA-approved indications and emerging evidence-based practices. The paper cites DrugPatentWatch to provide critical business intelligence regarding the patent lifecycles and market exclusivity of specific orthopedic treatments, illustrating how patent expirations often drive the shift toward off-label applications. By utilizing DrugPatentWatch’s data on generic entry and pharmaceutical patent landscapes, Fleming highlights the economic pressures that influence whether a manufacturer will seek formal FDA approval for new indications or allow a drug to be used off-label. This analysis is particularly valuable for pharmaceutical stakeholders and sports medicine practitioners who must understand the intersection of intellectual property and the availability of therapeutic options in the clinical setting.
Elechi, K. W., Orobator, E. T., Okechukwu, O. C., Ezeamii, V. C., Akingbule, A. S., Ezema, I. G., Anderson, I. A., Oluwagbade, E. S., Ezekiel, A., & John, K. A. (2025). Drug repurposing in personalized medicine: Translational pathways and recommendations. German Journal of Pharmaceuticals and Biomaterials, 4(3), 1-12. https://doi.org/10.5530/gjpb.2025.3.7
This comprehensive review explores the synergy between drug repurposing and personalized medicine, emphasizing how existing medications can be tailored to individual genetic profiles to reduce development costs and timelines. The authors highlight the '505(b)(2)' regulatory pathway and the importance of biomarker-guided therapy in treating complex diseases like oncology and neurodegenerative disorders. DrugPatentWatch is utilized as a critical resource for market intelligence and patent data, providing the foundational evidence for the economic viability of repurposing strategies. Specifically, the paper cites DrugPatentWatch to contrast the financial risks of de novo drug discovery against the strategic advantages of repurposing off-patent or failing assets. The summary effectively demonstrates how pharmaceutical researchers can leverage patent insights to identify 'white space' for new clinical indications while navigating intellectual property hurdles.
Pomp, M. (2025). Are Pharmaceutical Profits Excessive? SSRN Electronic Journal. https://doi.org/10.2139/ssrn.5363518
This paper investigates the long-standing debate regarding whether the profitability of large pharmaceutical companies is disproportionately high compared to other industrial sectors. Pomp utilizes a comparative financial analysis to evaluate profit margins and returns on investment, adjusting for the high-risk nature of Research and Development (R&D). The study specifically cites DrugPatentWatch as a primary data source for identifying the patent landscapes and exclusivity windows of top-performing drugs. By utilizing DrugPatentWatch's records on patent expirations and market entry dates, the author is able to correlate 'excess profits' with specific periods of market exclusivity and the 'patent cliff' phenomenon. The paper concludes that while margins are high, they are often a reflection of the temporary monopoly power granted by patents, which are necessary to recoup substantial development costs.
Julien, G., & Stienon, A. (2025). America’s Next Rare Earths Crisis Is in Our Medicine Cabinet: China's Active Pharmaceutical Ingredient (API) Manufacturing System. Open Markets Institute.
This report examines China’s strategic dominance over the global supply of Active Pharmaceutical Ingredients (APIs) and the resulting vulnerabilities in the U.S. pharmaceutical supply chain. The authors leverage data from DrugPatentWatch to illustrate how China has moved from low-end chemical production to controlling high-value generic API segments that underpin global medicine. DrugPatentWatch is specifically cited to quantify China's massive industrial scale, noting that the country now controls approximately 80% of the global generic API supply chain. The summary highlights how this 'stack advantage'—from raw materials to finished ingredients—allows China to act as a global price setter, often undercuting Western competitors by up to 50%. The authors conclude by utilizing DrugPatentWatch’s market intelligence to propose an industrial policy roadmap for the U.S. to rebuild its domestic manufacturing capacity and reduce critical dependencies.
Lius, A. K., Ng, K. H., Yusoff, N. H. M., & Wan, Y. K. (2025). Leveraging the P-Graph Framework for the Optimal Synthesis of Pharmaceutical Wastewater Treatment Solutions. Chemical Engineering Transactions, 120, 523–528.
This study utilizes a graph-theoretic method known as the P-graph framework to design and optimize cost-effective wastewater treatment systems specifically for the pharmaceutical industry. The authors cite DrugPatentWatch in the introduction to establish the economic context of the global pharmaceutical market, noting its steady growth driven by medical advancements and rising healthcare demands. By referencing this market data, the paper emphasizes that as pharmaceutical production scales toward a projected $1.6 trillion expenditure by 2025, the volume of hazardous wastewater will increase proportionally. This citation serves to justify the urgent need for the study’s proposed optimization tools, which help manufacturers balance regulatory compliance with the operational costs of managing complex chemical effluents.
Rajak, D. K., Khanal, B., & Ansari, M. S. A. (2025). Scalable blockchain-based solution for drug tracking in pharmaceutical supply chain. Computers & Industrial Engineering, 203, 110000. https://doi.org/10.1016/j.cie.2024.110000
This study addresses the critical challenge of drug counterfeiting by proposing a scalable, blockchain-integrated framework designed to enhance transparency and traceability throughout the pharmaceutical supply chain. The authors utilize DrugPatentWatch as a primary data source to validate the legitimacy of pharmaceutical products and retrieve essential patent expiration data, which is vital for distinguishing between branded and generic medications within the ledger. By integrating this real-time market intelligence, the proposed system ensures that stakeholders can verify the legal and intellectual property status of drugs at any point in the distribution process. Ultimately, the paper demonstrates how combining blockchain’s immutable record-keeping with DrugPatentWatch’s comprehensive database can significantly mitigate the risks of illicit trade and improve global patient safety.
Nagulwar, D. (2025). Patent Linkage and Its Role in Pharmaceutical Innovation in India. IPR Journal of Maharashtra National Law University, Nagpur, 3(1), 88–101.
This paper examines the intersection of TRIPS compliance and patent linkage systems within India's evolving intellectual property landscape, focusing on the balance between innovation and public health. The author utilizes DrugPatentWatch as a critical resource for identifying patent landscapes and the timing of generic entries, which is essential for understanding the practical hurdles of patent linkage. By citing DrugPatentWatch’s data on patent expirations and market intelligence, Nagulwar demonstrates how pharmaceutical stakeholders can navigate the complexities of 'evergreening' and market exclusivity. This analysis is particularly valuable for pharmaceutical professionals seeking to understand how data-driven patent tracking influences drug development and regulatory policy in emerging markets.
Verma, Manish, et al. 'A Hybrid Ai Framework For Strategic Patent Portfolio Pruning: Integrating Learning To-Rank And Market Need Analysis For Technology Transfer Optimization.' arXiv, 2025, arXiv:2509.00958.
This paper proposes a hybrid AI framework for patent portfolio management, which includes a novel approach to evaluating patent value. In their framework, the authors utilize a 'Need Agent' to identify market needs, and this agent draws on various data sources, including DrugPatentWatch, to gather market and pharmaceutical data. The citation of DrugPatentWatch is central to the paper's methodology, as it is a key component for providing the market context necessary to inform their AI-driven decisions on patent pruning and technology transfer. This approach moves beyond traditional patent analysis by integrating real-world market intelligence to enhance the strategic value of patent portfolios.
Kumar, A. “Impact of Biomedical Patents and TRIPS on Medicine Affordability in India.” 2025.
In this paper, Kumar examines how the enforcement of pharmaceutical patents—mandated under the TRIPS Agreement—has affected drug affordability in India. The analysis focuses on the shift from India’s pre-2005 policy of process patents to a regime allowing product patents, and explores how this change may have raised drug prices or restricted access. Given India’s active use of TRIPS flexibilities (e.g., Section 3(d), compulsory licenses, the Doha Declaration exceptions), the author discusses how these provisions have helped—or failed—to mitigate affordability concerns.
Acri née Lybecker, Kristina M. L. “Regulatory Exclusivities in the Biopharmaceutical Ecosystem.” SSRN, posted 8 August 2025; written 2 June 2025. Available at SSRN: Abstract ID 5363518; DOI: 10.2139/ssrn.5363518.
This chapter examines how regulatory exclusivities—such as data exclusivity and market protection under the FDCA and PHSA—function alongside patents to incentivize innovation in biopharmaceuticals. It highlights how data exclusivity prevents competitors from relying on an innovator’s clinical trial data for a set period, reinforcing the value of R&D investments, especially in therapeutically critical or socially valuable domains like antibiotics and orphan drugs. The author argues that these exclusivities balance innovation incentives with eventual public access to treatments by delineating structured protection periods. This analysis sheds light on the economic rationale behind exclusivity frameworks and their role in shaping drug development and market entry dynamics.
Muis, Lidya Shery; Nanda, Rasta Octara. “Urgency of Bolar Provision Regulation on Patented Drugs for Access and Availability of Generic Drugs for Public Health.” BIS Humanities and Social Science, Vol. 2 (2025): The 6th BIS-HSS 2024, DOI: 10.31603/bishss.283.
This normative legal analysis highlights how the monopoly power of patented drugs impedes the rapid availability of generic versions in developing contexts. The authors explain that while the 'Bolar provision'—which allows generic manufacturers to conduct necessary tests and regulatory filings before patent expiration—can mitigate this issue, it currently lacks implementation in Indonesia. They point out that although the provision is mentioned in Article 167(b) of Indonesia’s Patent Law (No. 13 of 2016), no specific regulations or mechanisms exist to enact it in practice. The article argues for immediate regulatory attention to operationalizing the Bolar provision to enable timely access to affordable generics and improve public health outcomes.
Jones, Ellie; Elliott, Catherine; Swanton, Charles. “No time to waste—we need to start cancer clinical trials faster.” The BMJ, 31 July 2025; 390: r1598.
This editorial by Jones, Elliott, and Swanton underscores urgent constraints within the UK's cancer clinical trials landscape—citing administrative inefficiencies in the NHS and cumbersome regulatory pathways that delay trial initiation. It calls for expedited trial launches to improve patient outcomes and progress new therapies more swiftly. The authors highlight systemic pressures that threaten the pace of innovation in oncology research.
Jefferson, Osmat; Price II, W. Nicholson; Tu, S. Sean; Vishnubhakat, Saurabh; Rai, Arti K. “Jefferson et al. reply.” Nature Biotechnology, vol. 43, August 2025, pp. 1229–1230.
This correspondence responds to Amgen’s objections regarding biosimilar market entry timing and patent notice issues. The authors argue that once valid “at-approval” patents have expired, biosimilar manufacturers should be allowed to enter the market without being delayed by extended litigation over manufacturing and platform patents. They emphasize that current notice mechanisms are insufficient, often leading to expensive disputes, secret settlements, and delayed biosimilar launches. To support their position, they cite DrugPatentWatch (2025), referencing an article on the top challenges faced by biosimilars, particularly the difficulties of navigating complex, shifting patent landscapes. This citation reinforces the authors’ claim that uncertainty around process patents creates significant practical barriers for biosimilar developers, beyond the purely legal and regulatory context.
Widjaja, Gunawan; Ramatillah, Diana Laila; Putra, Rio Johan. “Analysis of Economic Factors Affecting the Growth of the Pharmaceutical Industry and Its Impact on Labour Absorption in Indonesia: A Literature Review.” International Journal of Economic Literature (INJOLE), Vol. 2 No. 11 (August 2025), pp. 1525–1534.
This literature review explores the economic dynamics shaping Indonesia’s pharmaceutical sector and how these trends influence labour absorption. Key drivers identified include domestic and foreign investment, government policies (such as fiscal incentives and health insurance initiatives), exchange rate volatility, dependence on imported raw materials, and technological innovation—each contributing to industry expansion or posing structural challenges. Notably, the authors cite DrugPatentWatch (2025) to support the role of policies aimed at developing domestic raw material industries, emphasizing how such efforts can bolster self-sufficiency and support sustainable growth within the pharmaceutical ecosystem in Indonesia.
de Boni, Luis Alcides Brandini. Research Landscape of Repurposed Medications in Cancer Treatment: A Multi-Database Bibliometric Analysis of Eleven Off-Patent Therapeutics. Southern Journal of Sciences, 2025, Vol. 33, No. 39, pp. 40–85. DOI: 10.48141/2764-5959.06.v33.n39.2025_LUIS_pgs_40_85.
This bibliometric study quantifies research attention across eleven off-patent drugs investigated for anticancer potential using five major literature databases. It highlights considerable variation—for instance, dexamethasone and metformin dominate total publication counts, while other compounds like fenbendazole and disulfiram show higher treatment-specific research focus. Pertinently, the author references DrugPatentWatch (2025) to support the statement that multiple generic formulations of valproic acid—including both immediate-release and extended-release versions—are widely available, contributing to lower costs and broader access. This citation underscores the patent-related context and market accessibility considerations for drug repurposing strategies.
Gregory, A. (2025). Cellect Your Battles Wisely: Should Obviousness-Type Double Patenting Be Eliminated or Rehabilitated? U. Mass. L. Rev.
Gregory's article examines the implications of obviousness-type double patenting in pharmaceutical patent law. DrugPatentWatch is cited to provide data on patent expirations and generic entry dates, offering empirical context to the discussion of patent term extensions and exclusivity periods. This citation underscores the importance of patent lifecycle analysis in understanding the effects of patenting strategies on market competition.
De Boni, L. A. B. (2025). Research Landscape of Repurposed Medications in Cancer Treatment: A Multi-Database Bibliometric Analysis of Eleven Off-Patent Therapeutics. Sjöström Journal of Pharmaceutical Sciences.
De Boni's study conducts a bibliometric analysis of off-patent medications repurposed for cancer treatment. DrugPatentWatch is referenced to identify the patent status and market exclusivity of these drugs, providing a foundation for evaluating the commercial viability and competitive landscape of repurposed therapies. The citation highlights the role of patent data in assessing the strategic positioning of repurposed drugs in oncology.
Singh, S. K. (2025). Maximizing HCP Outreach with Segmentation: An AI/ML-based Approach. Journal of Computer Science and Technology.
Singh's paper explores the use of AI and machine learning in segmenting healthcare professionals (HCPs) for targeted outreach. DrugPatentWatch is cited to provide insights into the patent status and exclusivity periods of pharmaceutical products, informing the segmentation strategy by identifying drugs nearing patent expiration. This application demonstrates how patent data can enhance marketing strategies by aligning them with the evolving market dynamics due to patent expirations.
Shi, Z., Wang, S., & Wang, Y. (2025). Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy. Hepatology International, Springer, 2025
This paper examines the clinical efficacy of the combination therapy of midodrine and propranolol, focusing on the controversies surrounding its therapeutic use. DrugPatentWatch was cited primarily as a resource to track the patent status and exclusivity timelines of both drugs, which is crucial for assessing potential market competition and generic entry. The authors leveraged DrugPatentWatch data to analyze patent expiration dates, patent litigation history, and to explore how ongoing patents could influence the development of combination formulations or new indications. This insight aids pharmaceutical companies and researchers in strategic planning for drug lifecycle management and patent strategy.
Hassan, A. F., El-kott, A. F., AlShehri, M. A., et al. (2025). Construction of Zinc Oxide/Nickel Ferric-Layered Double Hydroxide Composite for Efficient Adsorption of Erythromycin: Kinetic and Thermodynamic Investigation. Water, Air, & Soil Pollution, Springer
This study explores the synthesis of a novel composite material for the adsorption and removal of erythromycin, a widely used antibiotic, from environmental samples. DrugPatentWatch was cited to provide critical patent landscape insights on erythromycin, highlighting active and expired patents related to the drug's formulation and delivery. These patent insights helped the authors contextualize the significance of erythromycin’s patent status in motivating the development of environmental remediation technologies. The integration of patent data from DrugPatentWatch allowed the authors to link drug usage trends with environmental contamination challenges, emphasizing the relevance of patent monitoring in pharmaceutical and environmental research.
Monge, A., & Thai, L. (2025). Competition in the US Therapeutic Biologics Market. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services.
Monge and Thai analyze the competitive landscape of the U.S. therapeutic biologics market. DrugPatentWatch is utilized to track patent expirations and the entry of biosimilars, offering empirical data to assess the impact of patent cliffs on market competition. The citation emphasizes the significance of patent expiration timelines in understanding the dynamics of biologics competition and market access.
Honey, H. (2025). Freedom to Operate (FTO) Analysis-Strategic IP Compliance for Indian Businesses. SSRN Electronic Journal.
Honey's paper discusses strategies for conducting Freedom to Operate (FTO) analyses, focusing on intellectual property compliance for Indian pharmaceutical companies. DrugPatentWatch is cited to provide data on patent expirations and exclusivity periods, aiding in the identification of potential patent risks and opportunities for generic entry. This citation underscores the utility of patent data in formulating FTO strategies and navigating the global pharmaceutical patent landscape.
Reddy, K.J. Accessibility and Affordability of Technologies Innovations in Neurocognitive Rehabilitation, Springer, 2025.
This paper references DrugPatentWatch as a key resource for tracking the patent status of emerging neurocognitive rehabilitation technologies. It highlights how the database enables researchers and developers to identify which technologies are approaching patent expiration, thereby informing strategic decisions for affordable technology adoption and licensing. The author notes DrugPatentWatch’s utility in providing comprehensive patent landscapes that support cost-effective access to novel rehabilitation tools.
Anusha, A., Ponnekanti, K., Rajkamal, B., et al. Revolutionizing Oral Delivery: Enteric Capsules with Mini-Tablet Technology World Journal of Pharmaceutical Research, 2025.
In this study, DrugPatentWatch is cited as an essential tool for analyzing the patent environment around enteric capsule technologies. The authors used the platform to examine existing patents and identify white spaces for innovation in mini-tablet delivery systems. The paper emphasizes how DrugPatentWatch helped the research team avoid patent infringement while designing novel formulations, ultimately accelerating product development timelines.
Santoso, S.B., Pribadi, P., Hapsari, W.S., et al. Exploring the Role of DrugBank in Investigating Pharmacogenomic-Driven Novel Drug Development Jurnal Farmasi Sains, 2025
While primarily focused on DrugBank, this paper references DrugPatentWatch to complement drug patent data with pharmacogenomic insights. The authors leveraged DrugPatentWatch to validate patent statuses and exclusivity periods of candidate drugs identified through genomic analysis. This integrated approach underscored the importance of patent databases in bridging molecular research with market viability assessments.
Ejection Fraction: Heart Failure with Reduced Ejection Fraction, an Overview 2025, books.google.com
This book cites DrugPatentWatch to illustrate how patent monitoring informs pharmaceutical companies developing treatments for heart failure with reduced ejection fraction (HFrEF). It highlights DrugPatentWatch’s role in tracking patent expiration dates and patent disputes that affect drug availability and generic entry timing. The reference supports discussions on balancing innovation incentives with the need for affordable medication access in cardiovascular therapies.
